申请人:Merck Sharp & Dohme Corp
公开号:US20150099891A1
公开(公告)日:2015-04-09
Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.
“(2R,3S,5R)-2-(2,5-二氟苯基)-5-[2-(甲磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-基]四氢-2H-吡喃-3-胺的新型晶体形态是强效的二肽基肽酶-IV抑制剂,可用于治疗非胰岛素依赖性(2型)糖尿病。本发明还涉及含有这些新型形态的制药组合物,制备这些形态及其制药组合物的工艺以及它们用于治疗2型糖尿病的用途。”